CL2018001868A1 - Análogos del egf(a) con sustituyentes de ácidos grasos. - Google Patents

Análogos del egf(a) con sustituyentes de ácidos grasos.

Info

Publication number
CL2018001868A1
CL2018001868A1 CL2018001868A CL2018001868A CL2018001868A1 CL 2018001868 A1 CL2018001868 A1 CL 2018001868A1 CL 2018001868 A CL2018001868 A CL 2018001868A CL 2018001868 A CL2018001868 A CL 2018001868A CL 2018001868 A1 CL2018001868 A1 CL 2018001868A1
Authority
CL
Chile
Prior art keywords
egf
fatty acid
analogues
compounds
acid substituents
Prior art date
Application number
CL2018001868A
Other languages
English (en)
Inventor
Jianhe Chen
Jesper F Lau
János Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning Thøgersen
Salka Elbøl Rasmussen
Patrick William Garibay
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2018001868A1 publication Critical patent/CL2018001868A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DERIVADOS DEL DOMINIO EGF(A) DE LDL-R, EN PARTICULAR A COMPUESTOS QUE COMPRENDEN UN ANÁLOGO PEPTÍDICO DE LA SECUENCIA DE EGF(A) SILVESTRE (LDL-R(293-332)) Y AL MENOS UN SUSTITUYENTE QUE COMPRENDE AL MENOS UN GRUPO DE ÁCIDO GRASO. LA INVENCIÓN SE REFIERE, ADEMÁS, A UNA COMPOSICIÓN FARMACÉUTICA DE ESTOS Y SU USO COMO MEDICAMENTO. LOS NOVEDOSOS COMPUESTOS DE EGF(A) DE LA INVENCIÓN SON ÚTILES COMO TRATAMIENTO, POR EJEMPLO, EN EL CAMPO DE LA DISMINUCIÓN DE COLESTEROL, DISLIPIDEMIA Y ENFERMEDAD CARDIOVASCULAR.
CL2018001868A 2016-01-13 2018-07-09 Análogos del egf(a) con sustituyentes de ácidos grasos. CL2018001868A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27

Publications (1)

Publication Number Publication Date
CL2018001868A1 true CL2018001868A1 (es) 2018-08-31

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001868A CL2018001868A1 (es) 2016-01-13 2018-07-09 Análogos del egf(a) con sustituyentes de ácidos grasos.

Country Status (26)

Country Link
US (2) US10822385B2 (es)
EP (1) EP3402811B1 (es)
JP (2) JP6797926B2 (es)
KR (1) KR102417487B1 (es)
CN (1) CN108473550B (es)
AU (1) AU2017207862B2 (es)
BR (1) BR112018013820A2 (es)
CA (1) CA3010756A1 (es)
CL (1) CL2018001868A1 (es)
CO (1) CO2018007440A2 (es)
DK (1) DK3402811T3 (es)
ES (1) ES2916998T3 (es)
HR (1) HRP20220720T1 (es)
HU (1) HUE058647T2 (es)
IL (1) IL260043A (es)
LT (1) LT3402811T (es)
MX (1) MX2018008681A (es)
MY (1) MY195199A (es)
PE (1) PE20181376A1 (es)
PH (1) PH12018501502A1 (es)
PL (1) PL3402811T3 (es)
RS (1) RS63298B1 (es)
RU (1) RU2747877C2 (es)
SA (1) SA518391996B1 (es)
SI (1) SI3402811T1 (es)
WO (1) WO2017121850A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
AR112760A1 (es) 2017-07-19 2019-12-11 Novo Nordisk As Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
JP2020527159A (ja) * 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
MX2021010767A (es) 2019-03-22 2021-09-28 3M Innovative Properties Company Sistema de proteccion contra caidas con sistema de monitoreo.
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
BR112022000529A2 (pt) 2019-08-07 2022-03-03 Novo Nordisk As Composição farmacêutica
MX2022004718A (es) 2019-11-07 2022-06-08 Novo Nordisk As Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
WO2023275675A2 (en) 2021-07-02 2023-01-05 3M Innovative Properties Company Aerial lift interlocked with fall-protection safety apparatus
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279276A1 (en) 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
AU2009238550B2 (en) * 2008-04-23 2014-11-27 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2012017774A1 (ja) * 2010-08-02 2012-02-09 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
KR20140041747A (ko) * 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
MY167234A (en) * 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
CA2880929A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
MY174727A (en) * 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP2017512457A (ja) 2014-02-21 2017-05-25 メディミューン，エルエルシー 抗ｐｃｓｋ９〜ｇｌｐ−１融合物および使用方法
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
AR112760A1 (es) 2017-07-19 2019-12-11 Novo Nordisk As Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
JP2020527159A (ja) 2017-07-19 2020-09-03 ノヴォ ノルディスク アー／エス Ｅｇｆ（ａ）類似体、その製造、製剤および使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Also Published As

Publication number Publication date
JP6797926B2 (ja) 2020-12-09
AU2017207862A1 (en) 2018-07-05
EP3402811B1 (en) 2022-03-30
DK3402811T3 (da) 2022-06-13
RU2018127882A (ru) 2020-02-13
KR102417487B1 (ko) 2022-07-06
MX2018008681A (es) 2018-09-17
US20200407409A1 (en) 2020-12-31
CO2018007440A2 (es) 2018-09-28
CN108473550A (zh) 2018-08-31
EP3402811A1 (en) 2018-11-21
IL260043A (en) 2018-07-31
PE20181376A1 (es) 2018-09-05
RU2747877C2 (ru) 2021-05-17
MY195199A (en) 2023-01-11
PH12018501502A1 (en) 2019-03-25
US10822385B2 (en) 2020-11-03
CA3010756A1 (en) 2017-07-20
BR112018013820A2 (pt) 2018-12-11
AU2017207862B2 (en) 2020-12-17
RU2018127882A3 (es) 2020-06-19
PL3402811T3 (pl) 2022-07-11
HUE058647T2 (hu) 2022-09-28
HRP20220720T1 (hr) 2022-09-30
KR20180100177A (ko) 2018-09-07
WO2017121850A1 (en) 2017-07-20
ES2916998T3 (es) 2022-07-06
JP2019505521A (ja) 2019-02-28
US20190016768A1 (en) 2019-01-17
RS63298B1 (sr) 2022-07-29
JP2021035989A (ja) 2021-03-04
LT3402811T (lt) 2022-06-10
SA518391996B1 (ar) 2021-07-14
SI3402811T1 (sl) 2022-06-30
CN108473550B (zh) 2022-11-22

Similar Documents

Publication Publication Date Title
CO2018007440A2 (es) Análogos del egf(a) con sustituyentes de ácidos grasos
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
BR112017010173A2 (pt) composição para tratamento de tecido
DOP2019000122A (es) Inhibidores de magl
ECSP19035377A (es) Inhibidores de magl
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
BR112017010177A2 (pt) composição para tratamento de tecido
MX2017012595A (es) Un extracto de indigo naturalis y un proceso para preparar el mismo.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2020001686A1 (es) Compuestos inhibidores del blanco mecanístico de rapamicina (mtor).
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017008454A (es) Peptidos y su uso en el tratamiento de la piel.
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CL2018001779A1 (es) Composición lípida vegetal para promover el crecimiento del cabello, método para promover el crecimiento del cabello y uso de dichos lípidos vegetales.
MX2017014128A (es) 2-tiopirimidinonas.
CL2017002229A1 (es) Inhibidores de bace1.